[
  {
    "ts": null,
    "headline": "How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism",
    "summary": "Regeneron Pharmaceuticals recently saw its consensus analyst price target move only slightly, shifting from $716.87 to $722.20. This marginal change reflects analysts' assessments of strong momentum in Regeneron's key assets, particularly Dupixent and Eylea, as well as positive clinical developments and robust quarterly results. Stay tuned to learn how you can track these shifts in sentiment as the Regeneron narrative continues to unfold. What Wall Street Has Been Saying The recent flow of...",
    "url": "https://finnhub.io/api/news?id=2a8883b3bdc94f224c790ee602e8001bc3ccf042d632c6175a098858cd5f0168",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758375257,
      "headline": "How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism",
      "id": 136828270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals recently saw its consensus analyst price target move only slightly, shifting from $716.87 to $722.20. This marginal change reflects analysts' assessments of strong momentum in Regeneron's key assets, particularly Dupixent and Eylea, as well as positive clinical developments and robust quarterly results. Stay tuned to learn how you can track these shifts in sentiment as the Regeneron narrative continues to unfold. What Wall Street Has Been Saying The recent flow of...",
      "url": "https://finnhub.io/api/news?id=2a8883b3bdc94f224c790ee602e8001bc3ccf042d632c6175a098858cd5f0168"
    }
  }
]